The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins

Zheng Li, Matthew S Block, Robert A. Vierkant, Zachary C. Fogarty, Stacey J Winham, Daniel W Visscher, Kimberly R. Kalli, Chen Wang, Ellen L Goode

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The tumor-associated inflammatory microenvironment may play a pivotal role in epithelial ovarian cancer (EOC) carcinogenesis and outcomes, but a detailed profile in patient-derived tumors is needed. Here, we investigated the expression of TLR4- and MyD88-associated markers in tumors from over 500 EOC patients using immunohistochemical staining. We demonstrate that high expression of TLR4 and MyD88 predicts poorer overall survival in patients with EOC; most likely, this is due to their association with serous histology and features of high tumor burden and aggressiveness, including stage, grade, and ascites at surgery. Combined TLR4 and MyD88 expression appears to serve as an independent risk factor for shortened survival time, even after covariate adjustment (both moderate HR 1.1 [95 % CI 0.7–1.8], both strong HR 2.1 [95 % CI 1.1–3.8], both weak as referent; p = 0.027). We reveal that in EOC tissues with elevated expression of both TLR4 and MyD88 and activated NF-κB signaling pathway, expression of hsp60, hsp70, beta 2 defensin, and HMGB1 are also enriched. In total, these results suggest that activation of TLR4/MyD88/NF-κB signaling by endogenous ligands may contribute to an inflammatory microenvironment that drives a more aggressive phenotype with poorer clinical outcome in EOC patients.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalTumor Biology
DOIs
StateAccepted/In press - Jul 26 2016

Fingerprint

Myeloid Differentiation Factor 88
beta-Defensins
HMGB1 Protein
Survival
Tumor Biomarkers
Tumor Burden
Ascites
Neoplasms
Histology
Carcinogenesis
Ovarian epithelial cancer
Staining and Labeling
Ligands
Phenotype

Keywords

  • Endogenous ligands
  • Epithelial ovarian cancer
  • Myeloid differentiation primary response gene eighty-eight (MyD88)
  • NF-κB signaling pathway
  • Toll-like receptor four (TLR4)

ASJC Scopus subject areas

  • Medicine(all)
  • Cancer Research

Cite this

The inflammatory microenvironment in epithelial ovarian cancer : a role for TLR4 and MyD88 and related proteins. / Li, Zheng; Block, Matthew S; Vierkant, Robert A.; Fogarty, Zachary C.; Winham, Stacey J; Visscher, Daniel W; Kalli, Kimberly R.; Wang, Chen; Goode, Ellen L.

In: Tumor Biology, 26.07.2016, p. 1-8.

Research output: Contribution to journalArticle

@article{4dee5010e4aa45e5a46e87dd49a055de,
title = "The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins",
abstract = "The tumor-associated inflammatory microenvironment may play a pivotal role in epithelial ovarian cancer (EOC) carcinogenesis and outcomes, but a detailed profile in patient-derived tumors is needed. Here, we investigated the expression of TLR4- and MyD88-associated markers in tumors from over 500 EOC patients using immunohistochemical staining. We demonstrate that high expression of TLR4 and MyD88 predicts poorer overall survival in patients with EOC; most likely, this is due to their association with serous histology and features of high tumor burden and aggressiveness, including stage, grade, and ascites at surgery. Combined TLR4 and MyD88 expression appears to serve as an independent risk factor for shortened survival time, even after covariate adjustment (both moderate HR 1.1 [95 {\%} CI 0.7–1.8], both strong HR 2.1 [95 {\%} CI 1.1–3.8], both weak as referent; p = 0.027). We reveal that in EOC tissues with elevated expression of both TLR4 and MyD88 and activated NF-κB signaling pathway, expression of hsp60, hsp70, beta 2 defensin, and HMGB1 are also enriched. In total, these results suggest that activation of TLR4/MyD88/NF-κB signaling by endogenous ligands may contribute to an inflammatory microenvironment that drives a more aggressive phenotype with poorer clinical outcome in EOC patients.",
keywords = "Endogenous ligands, Epithelial ovarian cancer, Myeloid differentiation primary response gene eighty-eight (MyD88), NF-κB signaling pathway, Toll-like receptor four (TLR4)",
author = "Zheng Li and Block, {Matthew S} and Vierkant, {Robert A.} and Fogarty, {Zachary C.} and Winham, {Stacey J} and Visscher, {Daniel W} and Kalli, {Kimberly R.} and Chen Wang and Goode, {Ellen L}",
year = "2016",
month = "7",
day = "26",
doi = "10.1007/s13277-016-5163-2",
language = "English (US)",
pages = "1--8",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - The inflammatory microenvironment in epithelial ovarian cancer

T2 - a role for TLR4 and MyD88 and related proteins

AU - Li, Zheng

AU - Block, Matthew S

AU - Vierkant, Robert A.

AU - Fogarty, Zachary C.

AU - Winham, Stacey J

AU - Visscher, Daniel W

AU - Kalli, Kimberly R.

AU - Wang, Chen

AU - Goode, Ellen L

PY - 2016/7/26

Y1 - 2016/7/26

N2 - The tumor-associated inflammatory microenvironment may play a pivotal role in epithelial ovarian cancer (EOC) carcinogenesis and outcomes, but a detailed profile in patient-derived tumors is needed. Here, we investigated the expression of TLR4- and MyD88-associated markers in tumors from over 500 EOC patients using immunohistochemical staining. We demonstrate that high expression of TLR4 and MyD88 predicts poorer overall survival in patients with EOC; most likely, this is due to their association with serous histology and features of high tumor burden and aggressiveness, including stage, grade, and ascites at surgery. Combined TLR4 and MyD88 expression appears to serve as an independent risk factor for shortened survival time, even after covariate adjustment (both moderate HR 1.1 [95 % CI 0.7–1.8], both strong HR 2.1 [95 % CI 1.1–3.8], both weak as referent; p = 0.027). We reveal that in EOC tissues with elevated expression of both TLR4 and MyD88 and activated NF-κB signaling pathway, expression of hsp60, hsp70, beta 2 defensin, and HMGB1 are also enriched. In total, these results suggest that activation of TLR4/MyD88/NF-κB signaling by endogenous ligands may contribute to an inflammatory microenvironment that drives a more aggressive phenotype with poorer clinical outcome in EOC patients.

AB - The tumor-associated inflammatory microenvironment may play a pivotal role in epithelial ovarian cancer (EOC) carcinogenesis and outcomes, but a detailed profile in patient-derived tumors is needed. Here, we investigated the expression of TLR4- and MyD88-associated markers in tumors from over 500 EOC patients using immunohistochemical staining. We demonstrate that high expression of TLR4 and MyD88 predicts poorer overall survival in patients with EOC; most likely, this is due to their association with serous histology and features of high tumor burden and aggressiveness, including stage, grade, and ascites at surgery. Combined TLR4 and MyD88 expression appears to serve as an independent risk factor for shortened survival time, even after covariate adjustment (both moderate HR 1.1 [95 % CI 0.7–1.8], both strong HR 2.1 [95 % CI 1.1–3.8], both weak as referent; p = 0.027). We reveal that in EOC tissues with elevated expression of both TLR4 and MyD88 and activated NF-κB signaling pathway, expression of hsp60, hsp70, beta 2 defensin, and HMGB1 are also enriched. In total, these results suggest that activation of TLR4/MyD88/NF-κB signaling by endogenous ligands may contribute to an inflammatory microenvironment that drives a more aggressive phenotype with poorer clinical outcome in EOC patients.

KW - Endogenous ligands

KW - Epithelial ovarian cancer

KW - Myeloid differentiation primary response gene eighty-eight (MyD88)

KW - NF-κB signaling pathway

KW - Toll-like receptor four (TLR4)

UR - http://www.scopus.com/inward/record.url?scp=84979663880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979663880&partnerID=8YFLogxK

U2 - 10.1007/s13277-016-5163-2

DO - 10.1007/s13277-016-5163-2

M3 - Article

C2 - 27460076

AN - SCOPUS:84979663880

SP - 1

EP - 8

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

ER -